(Q38092886)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23527888%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

Individualized therapy for metastatic colorectal cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23527888%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23527888%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Claudio Belluco

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23527888%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

A Silvestri

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23527888%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

A Huijbers

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23527888%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

R Pellicani

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23527888%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

E M Parasido

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23527888%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

M Pierobon

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23527888%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

E Petricoin

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23527888%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

L Liotta

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23527888%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

language of work or name

English

0 references

publication date

12 April 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23527888%20AND%20SRC:MED&resulttype=core&format=json

Journal of Internal Medicine

27 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23527888%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

274

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23527888%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23527888%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

1-24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23527888%20AND%20SRC:MED&resulttype=core&format=json

Gene expression profiling of colorectal cancer and metastases divides tumours according to their clinicopathological stage.

27 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

21 January 2018

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

International trends in colorectal cancer incidence rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Metastatic colorectal cancer-past, progress and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Pulmonary metastasectomy in colorectal cancer: a systematic review and quantitative synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

An update on chemotherapy of colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Challenges in the management of stage II colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Genetics, cytogenetics, and epigenetics of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Chromosomal instability confers intrinsic multidrug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Chromosomal instability, colorectal cancer and taxane resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

The application of single nucleotide polymorphism microarrays in cancer research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Frequent occurrence of uniparental disomy in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

High-throughput SNP/CGH approaches for the analysis of genomic instability in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

SNP-Array genotyping and spectral karyotyping reveal uniparental disomy as early mutational event in MSS- and MSI-colorectal cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to cetuximab in KRAS wild-type metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Genome-scale analysis of aberrant DNA methylation in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Long interspersed nuclear element-1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype-negative colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Receptor tyrosine kinases as targets for anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

21 January 2018

EGFR-targeted therapy

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Cellular responses to EGFR inhibitors and their relevance to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Responsiveness to cetuximab without mutations in EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Somatic mutations of EGFR in colorectal cancers and glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

EGFR FISH in colorectal cancer: what is the current reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

KRAS testing and its importance in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Molecular morphometric analysis shows relative intra-tumoural homogeneity for KRAS mutations in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Switching on kinases: oncogenic activation of BRAF and the PDGFR family

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Frequent PIK3CA gene amplification and its clinical significance in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Functional analysis of PIK3CA gene mutations in human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Mutant PIK3CA promotes cell growth and invasion of human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Oncogenic mutations as predictive factors in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Multiplexed Cell Signaling Analysis of Metastatic and Nonmetastatic Colorectal Cancer Reveals COX2-EGFR Signaling Activation as a Potential Prognostic Pathway Biomarker

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Vascular endothelial growth factor (VEGF) signaling in tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Angiogenesis in colorectal cancer: prognostic and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

A robust automated measure of average antibody staining in immunohistochemistry images

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

A portrait of tissue phosphoprotein stability in the clinical tissue procurement process

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Reverse-phase protein microarrays: application to biomarker discovery and translational medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Reverse phase protein microarrays: fluorometric and colorimetric detection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Protein pathway activation mapping of colorectal metastatic progression reveals metastasis-specific network alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Kinase substrate protein microarray analysis of human colon cancer and hepatic metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Validation of a phosphoprotein array assay for characterization of human tyrosine kinase receptor downstream signaling in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

REporting recommendations for tumor MARKer prognostic studies (REMARK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Significance of serum hepatocyte growth factor levels in patients with hepatocellular carcinoma undergoing hepatic resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Impact of Serum Hepatocyte Growth Factor on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non–Small Cell Lung Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Detection and characterization of carcinoma cells in the blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Challenges translating breast cancer gene signatures into the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

Prognostic Significance of Vascular Endothelial Growth Factor and Cyclooxygenase-2 in Patients with Rectal Cancer Treated with Preoperative Radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12070